Trump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.

Copy India’s pharmaceutical market is entering the proposed two-year transition period before the United States’ planned tariffs on imported generic medicines with broad-based domestic growth momentum...

The comments come as the Trump administration weighs higher import duties on medicines as part of a broader push to expand domestic manufacturing in the United States.